title: End stage polycystic kidney disease: indications and timing of native nephrectomy relative to kidney transplantation.
abstract: OBJECTIVE
  We evaluated the indications for and outcome of pre-transplant, concomitant and post-transplant native nephrectomy in patients with end stage polycystic kidney disease (PCKD).
  
  
  METHODS
  The records of 32 patients were retrospectively reviewed using the electronic database at our institution.
  
  
  RESULTS
  Between January 1992 and December 2002, 171 patients with end stage PCKD received a kidney transplant at University of California-San Francisco. A total of 32 patients (18.7%) underwent pre-transplant (7, group 1), concomitant (16, group 2) or post-transplant (9, group 3) native nephrectomy. Of these patients 25 underwent bilateral nephrectomy. Median followup was 18 months. Indications for nephrectomy were hematuria, a renal mass and chronic pain in group 1, lack of space in group 2 and urinary tract infection in group 3. Mean operative time +/- SEM was 231 +/- 14, 370 +/- 24 and 208 +/- 14 minutes in groups 1 to 3, respectively (p = 0.001). Mean intraoperative blood loss was 533 +/- 105, 573 +/- 155 and 522 +/- 181 ml in groups 1 to 3, respectively (p not significant). Two group 2 patients required blood transfusions. Postoperative complications requiring surgical intervention included wound dehiscence in group 1 and abdominal bleeding in group 3. Mean hospital stay was comparable among groups 1 to 3 at 7 +/- 0.7, 8.6 +/- 1.2 and 6.3 +/- 0.6 days, respectively (p not significant). At 3 months mean serum creatinine was not significantly different between groups 2 and 3 at 1.3 +/- 0.1 and 1.5 +/- 0.2 mg/dl, respectively.
  
  
  CONCLUSIONS
  Unilateral or bilateral nephrectomy for PCKD at transplantation is safe in terms of postoperative patient morbidity and graft function. We perform concomitant native nephrectomy when indicated, preferably in recipients of living donor kidney transplants.
authors.affiliation: Department of Urology, Charité University Hospital, Campus Charité Mitte, Schumannstrasse 20/21, 10117 Berlin, Germany. flofu@yahoo.com
authors.forename: T Florian
authors.initials: TF
authors.lastname: Fuller
authors.forename: Todd V
authors.initials: TV
authors.lastname: Brennan
authors.forename: Sandy
authors.initials: S
authors.lastname: Feng
authors.forename: Sang-Mo
authors.initials: SM
authors.lastname: Kang
authors.forename: Peter G
authors.initials: PG
authors.lastname: Stock
authors.forename: Chris E
authors.initials: CE
authors.lastname: Freise
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D002140:California; D003404:Creatinine / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007676:Kidney Failure, Chronic / Q000601:surgery*; D016030:Kidney Transplantation; D007902:Length of Stay; D008297:Male; D008499:Medical Records; D008875:Middle Aged; D009392:Nephrectomy / Q000009:adverse effects / Q000379:methods; D007690:Polycystic Kidney Diseases / Q000601:surgery*; D012086:Reoperation; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D003404:Creatinine